Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chohee Yun

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Cancer Research|October 19, 2007
TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signalingWook Jin, Chohee Yun, Hae-Suk Kim, et al.
Disease Markers|June 6, 2008
TGF-beta signaling in neuronal stem cellsChohee Yun, Jonathan Mendelson, Tiffany Blake, et al.
Clinical Therapeutics|July 15, 2014
Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjectsHyerang Roh, Hankil Son, Donghwan Lee, et al.
Clinical Therapeutics|July 2, 2013
Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjectsHankil Son, Hyerang Roh, Donghwan Lee, et al.
The Journal of Biological Chemistry|November 10, 2007
c-Src is required for tropomyosin receptor kinase C (TrkC)-induced activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathwayWook Jin, Chohee Yun, Joon Jeong, et al.
Clinical and Translational Science|September 9, 2021
Evaluation of the potential drug interactions mediated through P-gp, OCT2, and MATE1/2K with filgotinib in healthy subjectsChia-Hsiang Hsueh, Kacey Anderson, Gong Shen, et al.
Cancer Research|April 6, 2007
Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-SrcWook Jin, Chohee Yun, Amy Hobbie, et al.
Clinical Pharmacology in Drug Development|December 5, 2019
Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy SubjectsKacey Anderson, Yan Xin, Hao Zheng, et al.
Carcinogenesis|August 31, 2010
TrkC plays an essential role in breast tumor growth and metastasisWook Jin, Gyoung Mi Kim, Min Soo Kim, et al.
Nature Communications|June 21, 2019
Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseasesSamuel J S Rubin, Lawrence Bai, Yeneneh Haileselassie, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Cancer Research|October 19, 2007
TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signalingWook Jin, Chohee Yun, Hae-Suk Kim, et al.
Disease Markers|June 6, 2008
TGF-beta signaling in neuronal stem cellsChohee Yun, Jonathan Mendelson, Tiffany Blake, et al.
Clinical Therapeutics|July 15, 2014
Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjectsHyerang Roh, Hankil Son, Donghwan Lee, et al.
Clinical Therapeutics|July 2, 2013
Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjectsHankil Son, Hyerang Roh, Donghwan Lee, et al.
The Journal of Biological Chemistry|November 10, 2007
c-Src is required for tropomyosin receptor kinase C (TrkC)-induced activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathwayWook Jin, Chohee Yun, Joon Jeong, et al.
Clinical and Translational Science|September 9, 2021
Evaluation of the potential drug interactions mediated through P-gp, OCT2, and MATE1/2K with filgotinib in healthy subjectsChia-Hsiang Hsueh, Kacey Anderson, Gong Shen, et al.
Cancer Research|April 6, 2007
Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-SrcWook Jin, Chohee Yun, Amy Hobbie, et al.
Clinical Pharmacology in Drug Development|December 5, 2019
Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy SubjectsKacey Anderson, Yan Xin, Hao Zheng, et al.
Carcinogenesis|August 31, 2010
TrkC plays an essential role in breast tumor growth and metastasisWook Jin, Gyoung Mi Kim, Min Soo Kim, et al.
Nature Communications|June 21, 2019
Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseasesSamuel J S Rubin, Lawrence Bai, Yeneneh Haileselassie, et al.
Pageof 2